US FDA approves lung preservation machine

The approval of the XVIVO Perfusion System could lead to more successful transplants of lungs for people with cystic fibrosis and other deadly respiratory diseases.
Source: The Economic Times - Category: Consumer Health News Source Type: news

Related Links:

Publication date: Available online 24 May 2018 Source:Journal of the Academy of Nutrition and Dietetics Author(s): Mary Rozga, Deepa Handu
Source: Journal of the Academy of Nutrition and Dietetics - Category: Nutrition Source Type: research
Pulmonary exacerbations (PEx) in children with cystic fibrosis (CF) are frequently treated in the outpatient setting with oral antibiotics. However, little is known about the characteristics of PEx managed on an outpatient basis and the effectiveness of oral antibiotic therapy. We sought to prospectively evaluate clinical and laboratory changes associated with oral antibiotic treatment for PEx.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Original Article Source Type: research
Urinary tract stones are a common problem in a general population but increasingly so in cystic fibrosis (CF) patients as survival improves. Mechanisms of stone formation are discussed, particularly those unique to CF patients. Modalities of treatment and the decision making process in this choice is outlined as well as possible future preventative strategies.
Source: Paediatric Respiratory Reviews - Category: Respiratory Medicine Authors: Tags: The 2017 Royal Society Of Medicine Cystic Fibrosis Symposium Source Type: research
Condition:   Cystic Fibrosis Interventions:   Drug: TEZ/IVA;   Drug: IVA;   Drug: Placebo Sponsor:   Vertex Pharmaceuticals Incorporated Recruiting
Source: - Category: Research Source Type: clinical trials
Publication date: 25 August 2018 Source:International Journal of Pharmaceutics, Volume 547, Issues 1–2 Author(s): Sergey Zaichik, Christian Steinbring, Claudia Menzel, Ludwig Knabl, Dorothea Orth-Höller, Helmut Ellemunter, Katharina Niedermayr, Andreas Bernkop-Schnürch The aim of this study was to develop a self-emulsifying drug delivery system (SEDDS) containing the fluoroquinolone antibiotic ciprofloxacin (CIP) exhibiting highly mucus permeating properties and antimicrobial activity in in vitro models. Various SEDDS formulations were developed and evaluated regarding droplet size, polydispersity index, z...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Publication date: 25 August 2018 Source:International Journal of Pharmaceutics, Volume 547, Issues 1–2 Author(s): The-Thien Tran, Celine Vidaillac, Hong Yu, Valerie F.L. Yong, Dan Roizman, Ravishankar Chandrasekaran, Albert Y.H. Lim, Teck Boon Low, Gan Liang Tan, John A. Abisheganaden, Mariko Siyue Koh, Jeanette Teo, Sanjay H. Chotirmall, Kunn Hadinoto Non-cystic fibrosis bronchiectasis (NCFB) characterized by permanent bronchial dilatation and recurrent infections has been clinically managed by long-term intermittent inhaled antibiotic therapy among other treatments. Herein we investigated dry powder inhaler (DPI) ...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Regular airway clearance by chest physiotherapy and/or exercise is critical to lung health in cystic fibrosis (CF). Combination of cycling exercise and chest physiotherapy using the Flutter ® device on sputum p...
Source: BMC Pulmonary Medicine - Category: Respiratory Medicine Authors: Tags: Research article Source Type: research
Airway disease is a primary cause of morbidity and early mortality for patients with cystic fibrosis (CF). Cell transplantation therapy has proven successful for treating immune disorders and may have the pote...
Source: Stem Cell Research and Therapy - Category: Stem Cells Authors: Tags: Research Source Type: research
This study is a retrospective cohort study of 162 adult CF patients admitted to the University of Utah Hospital between January 1, 2008 and May 15, 2014 for treatment of an APE with both a CI BL and intravenous tobramycin. We extracted the administered doses of CI BL and tobramycin along with serum drug concentrations and calculated medication clearance rates. The primary outcome was change in clearance rates of CI BL between day 2 and day 7 of APE treatment. RESULTS: BL clearance rate increased 20.7% (95% CI, 11.42 - 32.49; p
Source: Chest - Category: Respiratory Medicine Authors: Tags: Chest Source Type: research
CONCLUSION: This study mapped existing genetic variations in B. cenocepacia associated with notorious outcomes in CF patients, and the data obtained provide comprehensive, genome-inferred insights and multifactorial examination of an important human pathogen. PMID: 29897328 [PubMed - as supplied by publisher]
Source: Journal of Medical Microbiology - Category: Microbiology Authors: Tags: J Med Microbiol Source Type: research
More News: Cystic Fibrosis | Health | Lung Transplant | Perfusion | Respiratory Medicine | Transplants